[go: up one dir, main page]

UA95996C2 - Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом - Google Patents

Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом

Info

Publication number
UA95996C2
UA95996C2 UAA200907146A UAA200907146A UA95996C2 UA 95996 C2 UA95996 C2 UA 95996C2 UA A200907146 A UAA200907146 A UA A200907146A UA A200907146 A UAA200907146 A UA A200907146A UA 95996 C2 UA95996 C2 UA 95996C2
Authority
UA
Ukraine
Prior art keywords
specifically binds
antibody fragment
binds human
molecule
fab antibody
Prior art date
Application number
UAA200907146A
Other languages
English (en)
Ukrainian (uk)
Inventor
Келли Реней Бейлз
Томас Френк Бамол
Чи-кинь Чоу
Рональд Бредли Дематтос
Райан Джон Хансен
Ума Кучиботла
Цзижон Лу
Петер Коулон Макдоннелл
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39332186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95996(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA95996C2 publication Critical patent/UA95996C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к молекуле, которая содержит фрагмент антитела, которое специфически связывает человеческий Аβ пептид между аминокислотными положениями 13-28, в которой молекула полиэтиленгликоля ковалентно присоединена к гипервариабельному участку тяжелой цепи этого антитела в положении 56 последовательности SEQ ID NO:2. Изобретение также относится к композиции, которая содержит указанную молекулу, и применению данной молекулы для изготовления лекарственного средства для предотвращения или лечения состояния, связанного с активностью Аβ пептида.
UAA200907146A 2007-01-18 2008-01-09 Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом UA95996C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88543907P 2007-01-18 2007-01-18

Publications (1)

Publication Number Publication Date
UA95996C2 true UA95996C2 (ru) 2011-09-26

Family

ID=39332186

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907146A UA95996C2 (ru) 2007-01-18 2008-01-09 Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом

Country Status (27)

Country Link
US (1) US8066999B2 (ru)
EP (2) EP2842967B1 (ru)
JP (2) JP5307030B2 (ru)
KR (2) KR101160385B1 (ru)
CN (2) CN101981053B (ru)
AR (1) AR064944A1 (ru)
AU (1) AU2008206555B2 (ru)
BR (1) BRPI0806715A2 (ru)
CA (1) CA2675847C (ru)
CL (1) CL2008000121A1 (ru)
CY (2) CY1116157T1 (ru)
DK (1) DK2121754T3 (ru)
EA (1) EA020979B1 (ru)
ES (2) ES2615454T3 (ru)
HK (1) HK1190623A1 (ru)
HR (2) HRP20150237T1 (ru)
IL (2) IL199838A (ru)
LT (1) LT2842967T (ru)
MX (1) MX2009007691A (ru)
PE (1) PE20081634A1 (ru)
PL (1) PL2121754T3 (ru)
PT (2) PT2121754E (ru)
RS (1) RS53948B1 (ru)
SI (2) SI2121754T1 (ru)
TW (1) TW200836763A (ru)
UA (1) UA95996C2 (ru)
WO (1) WO2008088983A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2310412T3 (en) 2008-06-20 2018-05-28 Novartis Ag IMMUNOGLOBULINES WITH REDUCED AGGREGATION
CN102099809B (zh) 2008-06-20 2014-05-07 诺华股份有限公司 识别蛋白质中大分子结合区域和易聚集区域的方法及其用途
JP5739880B2 (ja) * 2009-06-04 2015-06-24 ノバルティス アーゲー ＩｇＧ結合のための部位を同定するための方法
EA201201227A1 (ru) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2015036553A1 (en) * 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
AU2016353552B2 (en) 2015-11-09 2022-01-06 The University Of British Columbia N-terminal epitopes in Amyloid beta and conformationally-selective antibodies thereto
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
EP3484919A4 (en) 2016-07-18 2020-03-04 The University of British Columbia ANTI-BETA-AMYLOID ANTIBODIES
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3070085A1 (en) 2017-07-18 2019-01-24 Promis Neurosciences Inc. Antibodies to amyloid beta
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
US20210140980A1 (en) * 2018-01-04 2021-05-13 Septa Therapeutics, Inc. Septapeptides associated with neurodegeneracy
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU692237B2 (en) 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5668651A (en) * 1994-03-18 1997-09-16 Sharp Kabushiki Kaisha Polymer-wall LCD having liquid crystal molecules having a plane-symmetrical bend orientation
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6227999B1 (en) 1997-07-09 2001-05-08 Transmisiones Tsp, S.A. De C.V. Method and apparatus for operating a clutch in an automated mechanical transmission
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
AU8777898A (en) 1997-08-11 1999-03-01 Chiron Corporation Methods for genetically modifying t cells
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
IL139095A0 (en) 1998-05-21 2001-11-25 Univ Tennessee Res Corp Methods for amyloid removal using anti-amyloid antibodies
US6582945B1 (en) 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
AU6524500A (en) 1999-08-04 2001-03-05 Northwestern University Amyloid beta protein (globular assembly and uses thereof)
AU784568B2 (en) 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP3070100B1 (en) 2000-02-24 2021-07-07 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU9063801A (en) 2000-09-06 2002-03-22 Aventis Pharma Sa Methods and compositions for diseases associated with amyloidosis
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20040241164A1 (en) 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
AU2002329775C1 (en) 2001-08-17 2011-04-07 Eli Lilly And Company Assay method for alzheimer's disease
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
DK1416965T3 (da) 2001-08-17 2008-05-05 Univ Washington Assayfremgangsmåde til Alzheimers sygdom
US7166478B2 (en) 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
AU2003223474B2 (en) 2002-04-25 2008-09-04 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
KR101025143B1 (ko) * 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
US7575747B2 (en) * 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
ATE414106T1 (de) * 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
AU2005293752A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition

Also Published As

Publication number Publication date
DK2121754T3 (en) 2015-02-23
CA2675847A1 (en) 2008-07-24
IL230876A (en) 2016-06-30
RS53948B1 (en) 2015-08-31
KR20090101941A (ko) 2009-09-29
CA2675847C (en) 2014-12-30
EP2121754A1 (en) 2009-11-25
PT2842967T (pt) 2017-01-13
SI2121754T1 (sl) 2015-03-31
CL2008000121A1 (es) 2008-07-25
MX2009007691A (es) 2009-07-29
CN101981053A (zh) 2011-02-23
JP2010522141A (ja) 2010-07-01
KR101414847B1 (ko) 2014-07-03
US20100015155A1 (en) 2010-01-21
PE20081634A1 (es) 2008-11-22
CY1118554T1 (el) 2017-07-12
IL230876A0 (en) 2014-03-31
CN103479998B (zh) 2015-11-18
AU2008206555B2 (en) 2013-07-04
EA200970694A1 (ru) 2010-02-26
EP2842967A1 (en) 2015-03-04
CN101981053B (zh) 2013-11-13
KR101160385B1 (ko) 2012-07-10
KR20140015123A (ko) 2014-02-06
JP5782479B2 (ja) 2015-09-24
JP2013241420A (ja) 2013-12-05
PT2121754E (pt) 2015-05-11
WO2008088983A1 (en) 2008-07-24
IL199838A (en) 2014-03-31
BRPI0806715A2 (pt) 2011-09-13
ES2535641T3 (es) 2015-05-13
EP2121754B1 (en) 2015-02-11
CN103479998A (zh) 2014-01-01
JP5307030B2 (ja) 2013-10-02
PL2121754T3 (pl) 2015-07-31
TW200836763A (en) 2008-09-16
CY1116157T1 (el) 2017-02-08
LT2842967T (lt) 2017-02-27
EP2842967B1 (en) 2016-11-30
EA020979B1 (ru) 2015-03-31
HK1190623A1 (zh) 2014-07-11
ES2615454T3 (es) 2017-06-07
AU2008206555A1 (en) 2008-07-24
HRP20161677T1 (hr) 2017-01-27
US8066999B2 (en) 2011-11-29
HRP20150237T1 (hr) 2015-04-10
SI2842967T1 (sl) 2017-01-31
IL199838A0 (en) 2010-04-15
AR064944A1 (es) 2009-05-06

Similar Documents

Publication Publication Date Title
UA95996C2 (ru) Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
IL206641B (en) Recombinant or humanized or isolated antibody or chimeric antibody, or an antibody-binding fragment thereof that selectively binds to a new epitope of humanized amyloid a peptide, a pharmaceutical preparation containing the antibody and its use for the preparation of a pharmaceutical compound for the treatment of amyloidosis
WO2006087637A3 (en) Anti her2/neu antibody
WO2010005566A3 (en) Notch-binding agents and antagonists and methods of use thereof
WO2006013472A3 (en) Novel anti-igf-ir antibodies and uses thereof
WO2013184960A3 (en) Chimeric fibroblast growth factor 23 proteins and methods of use
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
NZ593173A (en) Osteonectin (Secreted Protein, Acidic, Rich in Cysteines (SPARC)) binding ScFvS
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
NZ598063A (en) Gram-positive bacteria specific binding compounds
TN2010000128A1 (en) Antibodies specific for the protofibril form of beta-amyloid protein
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
WO2012047724A4 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
GEP20135826B (en) Novel antibodies used to treat cancer
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
NZ608502A (en) Polypeptides that bind to human complement component c5
NZ601591A (en) Methods for treating pancreatic cancer
WO2005103084A3 (en) Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
RS52802B (en) USE OF PEPTIDS RELATING TO TPO RECEPTOR
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist